非肌肉浸润性膀胱癌的抗体-药物偶联物:现状和未来发展。

IF 2.2 3区 医学 Q2 UROLOGY & NEPHROLOGY
Current Opinion in Urology Pub Date : 2025-11-01 Epub Date: 2025-08-22 DOI:10.1097/MOU.0000000000001330
Francesco M Bracco, Chris H M Wong, Jeremy Y C Teoh
{"title":"非肌肉浸润性膀胱癌的抗体-药物偶联物:现状和未来发展。","authors":"Francesco M Bracco, Chris H M Wong, Jeremy Y C Teoh","doi":"10.1097/MOU.0000000000001330","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Antibody-drug conjugates (ADCs) have recently emerged as a promising targeted therapeutic strategy in urothelial carcinoma, and their application in nonmuscle invasive bladder cancer (NMIBC) is an evolving frontier. This review is timely as it synthesizes recent advances in ADC development for NMIBC, addressing critical unmet needs among both Bacillus Calmette-Guérin (BCG) naïve high-risk and BCG-unresponsive patients.</p><p><strong>Recent findings: </strong>The literature reveals that ADCs that target HER2, Trop-2, Nectin-4 are under active investigation. Several retrospective and prospective studies have reported encouraging complete response rates, durable event-free survival, and manageable safety profiles with these agents. Current clinical trials are evaluating ADCs as monotherapy or in combination with immune checkpoint inhibitors (e.g., durvalumab, tislelizumab) and intravesical therapies, aiming to refine dosing regimens and maximize therapeutic efficacy.</p><p><strong>Summary: </strong>The findings underscore the potential of ADCs to revolutionize NMIBC management by providing novel bladder-sparing strategies in patients traditionally limited by BCG failure. Future research should concentrate on optimizing patient selection, treatment sequencing, and combination strategies to improve long-term outcomes, enhancing survival and quality of life.</p>","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"653-660"},"PeriodicalIF":2.2000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development.\",\"authors\":\"Francesco M Bracco, Chris H M Wong, Jeremy Y C Teoh\",\"doi\":\"10.1097/MOU.0000000000001330\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Antibody-drug conjugates (ADCs) have recently emerged as a promising targeted therapeutic strategy in urothelial carcinoma, and their application in nonmuscle invasive bladder cancer (NMIBC) is an evolving frontier. This review is timely as it synthesizes recent advances in ADC development for NMIBC, addressing critical unmet needs among both Bacillus Calmette-Guérin (BCG) naïve high-risk and BCG-unresponsive patients.</p><p><strong>Recent findings: </strong>The literature reveals that ADCs that target HER2, Trop-2, Nectin-4 are under active investigation. Several retrospective and prospective studies have reported encouraging complete response rates, durable event-free survival, and manageable safety profiles with these agents. Current clinical trials are evaluating ADCs as monotherapy or in combination with immune checkpoint inhibitors (e.g., durvalumab, tislelizumab) and intravesical therapies, aiming to refine dosing regimens and maximize therapeutic efficacy.</p><p><strong>Summary: </strong>The findings underscore the potential of ADCs to revolutionize NMIBC management by providing novel bladder-sparing strategies in patients traditionally limited by BCG failure. Future research should concentrate on optimizing patient selection, treatment sequencing, and combination strategies to improve long-term outcomes, enhancing survival and quality of life.</p>\",\"PeriodicalId\":11093,\"journal\":{\"name\":\"Current Opinion in Urology\",\"volume\":\" \",\"pages\":\"653-660\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MOU.0000000000001330\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOU.0000000000001330","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

综述目的:抗体-药物偶联物(adc)最近成为尿路上皮癌的一种有前景的靶向治疗策略,其在非肌肉浸润性膀胱癌(NMIBC)中的应用是一个不断发展的前沿。这篇综述是及时的,因为它综合了NMIBC ADC开发的最新进展,解决了卡介苗naïve高风险和卡介苗无反应患者的关键未满足需求。最近的发现:文献显示靶向HER2, Trop-2, Nectin-4的adc正在积极研究中。一些回顾性和前瞻性研究报告了这些药物令人鼓舞的完全缓解率、持久的无事件生存期和可控的安全性。目前的临床试验正在评估adc作为单一治疗或与免疫检查点抑制剂(例如,durvalumab, tislelizumab)和膀胱内治疗联合使用,旨在完善给药方案并最大限度地提高治疗效果。摘要:研究结果强调了adc通过为传统上因BCG失败而受限的患者提供新颖的膀胱保留策略来彻底改变NMIBC管理的潜力。未来的研究应集中于优化患者选择、治疗顺序和联合策略,以改善长期预后,提高生存率和生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development.

Purpose of review: Antibody-drug conjugates (ADCs) have recently emerged as a promising targeted therapeutic strategy in urothelial carcinoma, and their application in nonmuscle invasive bladder cancer (NMIBC) is an evolving frontier. This review is timely as it synthesizes recent advances in ADC development for NMIBC, addressing critical unmet needs among both Bacillus Calmette-Guérin (BCG) naïve high-risk and BCG-unresponsive patients.

Recent findings: The literature reveals that ADCs that target HER2, Trop-2, Nectin-4 are under active investigation. Several retrospective and prospective studies have reported encouraging complete response rates, durable event-free survival, and manageable safety profiles with these agents. Current clinical trials are evaluating ADCs as monotherapy or in combination with immune checkpoint inhibitors (e.g., durvalumab, tislelizumab) and intravesical therapies, aiming to refine dosing regimens and maximize therapeutic efficacy.

Summary: The findings underscore the potential of ADCs to revolutionize NMIBC management by providing novel bladder-sparing strategies in patients traditionally limited by BCG failure. Future research should concentrate on optimizing patient selection, treatment sequencing, and combination strategies to improve long-term outcomes, enhancing survival and quality of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Opinion in Urology
Current Opinion in Urology 医学-泌尿学与肾脏学
CiteScore
5.00
自引率
4.00%
发文量
140
审稿时长
6-12 weeks
期刊介绍: ​​​​​​​​Current Opinion in Urology delivers a broad-based perspective on the most recent and most exciting developments in urology from across the world. Published bimonthly and featuring ten key topics – including focuses on prostate cancer, bladder cancer and minimally invasive urology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信